The Japan cell culture media market was valued at USD 470 million in 2025. This market is expected to reach USD 1.26 billion by 2036, growing from USD 515 million in 2026, at a CAGR of 9.4% from 2026 to 2036.

The market covers the growth media, including serum-free and chemically defined media, classical and basal media, specialty and stem-cell media, and sera, used to grow cells for biopharmaceutical production, vaccines, cell and gene therapy and regenerative medicine, research, and cultivated meat in Japan. Cell culture media are a critical input to biologics manufacturing, where cells such as Chinese hamster ovary lines produce monoclonal antibodies and other therapies, and to Japan's regenerative-medicine sector, where the country pioneered induced pluripotent stem cell science. Demand is driven by growth in biologics and biosimilar manufacturing, by the expansion of cell and gene therapy and regenerative medicine, by the shift to serum-free and chemically defined media, and by emerging cultivated meat. Japan is a mature, high-value market with demanding quality requirements, and it imports about half of its consumption while hosting two globally significant media producers.

Key Highlights – Japan Cell Culture Media Market

• The Japan cell culture media market is expected to reach USD 1.26 billion by 2036, at a CAGR of 9.4% from 2026 to 2036, driven by biologics manufacturing, cell and gene therapy, the shift to serum-free media, and cultivated meat.
• Serum-free media leads. Serum-free and chemically defined media account for the largest share, around 51% in 2026, reflecting regulatory preference for animal-component-free manufacturing and strong adoption in biologics workflows using CHO, HEK293 and Vero cells.
• Regenerative medicine is a growth engine. Japan's regenerative-medicine market, where the country pioneered induced pluripotent stem cells, was valued at about USD 1.34 billion in 2024 and is projected to reach about USD 3.09 billion by 2030, with about 20 regenerative products approved as of March 2024.
• Domestic majors invest in capacity. Ajinomoto, which created Japan's first serum-free medium in the 1980s and the StemFit medium for stem cells, and FUJIFILM Irvine Scientific, which FUJIFILM acquired for about USD 800 million and which manufactures media in Saitama and Aichi, anchor domestic supply.
• Clinical-grade media localise. Ajinomoto Kohjin Bio operates as the first contract manufacturer in Japan specialising in clinical-grade culture media for cell and gene therapy, supporting domestic regenerative-medicine production.
• Cultivated meat is emerging. Japanese cellular-agriculture company IntegriCulture developed a serum-free CulNet system and reported reaching profitability in 2025, pointing to a new, food-grade media application.
• Key companies include Ajinomoto Co., Inc., FUJIFILM Irvine Scientific, Inc., Thermo Fisher Scientific, Merck KGaA, and FUJIFILM Wako Pure Chemical Corporation.

Report Overview

The Japan cell culture media market covers the media used to grow cells across biopharmaceutical production, vaccines, cell and gene therapy and regenerative medicine, academic and research use, and cultivated meat, spanning serum-free and chemically defined media, classical and basal media such as DMEM and RPMI, specialty and stem-cell media, and sera. Laboratory plasticware, bioreactors and downstream processing are outside the scope except where media are the subject. The market is mature and high-value, with demanding quality requirements, a premium on serum-free and clinical-grade media, and about half of consumption imported. Demand is shaped by biologics manufacturing, regenerative medicine, and the shift away from animal-derived components. This report examines the size, drivers, product types, applications, end users, cell types, pricing, regional clusters, competition, recent developments, and outlook of the market, and provides recommendations. Sizing is built bottom-up from biologics and biosimilar manufacturing demand, cell and gene therapy and regenerative medicine, research use, and emerging cultivated meat, and reflects media value across domestic production and imports.

Key Market Dynamics

Market Drivers

The main drivers of the Japan cell culture media market are growth in biologics and biosimilar manufacturing, the expansion of cell and gene therapy and regenerative medicine, and the shift to serum-free and chemically defined media. Biologics manufacturing is the primary driver, as the production of monoclonal antibodies, biosimilars and vaccines in cell lines such as CHO, HEK293 and Vero consumes large volumes of media, and Japan is building biologics manufacturing capacity, with contract manufacturers such as AGC Biologics operating a cell-therapy and biologics site in Yokohama and CMIC opening antibody-production capacity. Cell and gene therapy and regenerative medicine are strong drivers, as Japan pioneered induced pluripotent stem cell science through Professor Yamanaka of Kyoto University, its regenerative-medicine market was valued at about USD 1.34 billion in 2024 and is projected to reach about USD 3.09 billion by 2030, and about 20 regenerative products had been approved as of March 2024 under a supportive PMDA framework. The shift to serum-free and chemically defined media is a driver of value, as regulatory preference for animal-component-free manufacturing and the need for reproducibility move demand toward higher-value media, which account for about 51% of the market. These factors, biologics manufacturing, regenerative medicine, and serum-free adoption, are the main drivers, supported by government funding through AMED and by emerging cultivated meat.

Key Opportunities

The market offers opportunities in serum-free and chemically defined media, in clinical-grade media for cell and gene therapy, and in food-grade media for cultivated meat. Serum-free and chemically defined media are a leading opportunity, because regulatory and quality requirements favour animal-component-free, reproducible media, and these command premium prices in biologics manufacturing. Clinical-grade media for cell and gene therapy are an opportunity as regenerative medicine scales, since therapies require GMP media, and Ajinomoto Kohjin Bio operates as the first contract manufacturer in Japan specialising in clinical-grade culture media for cell and gene therapy. Food-grade media for cultivated meat is an emerging opportunity, as cellular-agriculture companies such as IntegriCulture develop serum-free systems and require large volumes of low-cost, food-grade media. These areas, serum-free media, clinical-grade media, and cultivated-meat media, are the main opportunities, alongside domestic GMP capacity that reduces reliance on imports.

Market Trends

Current trends include the shift to serum-free and chemically defined media, localisation of clinical-grade GMP media, capacity investment by domestic majors, and emerging cultivated-meat media. The shift to serum-free and chemically defined media is the defining trend, driven by regulatory preference for animal-component-free manufacturing and reproducibility, with these media at about 51% of the market. Localisation of clinical-grade GMP media is a trend tied to regenerative medicine, with Ajinomoto Kohjin Bio providing domestic clinical-grade media for cell and gene therapy. Capacity investment by domestic majors is a structural trend, with Ajinomoto expanding stem-cell and clinical media and FUJIFILM Irvine Scientific manufacturing media in Saitama and Aichi and investing globally in capacity. Emerging cultivated-meat media is a new trend, as IntegriCulture and partners advance serum-free food-grade media. These trends indicate a mature market moving toward higher-value, animal-component-free and clinical-grade media.

Report Summary

Segmental Analysis

Market by Product Type

By product type, the market comprises serum-free and chemically defined media, classical and basal media, specialty and stem-cell media, and serum-containing media. Serum-free and chemically defined media hold the largest share, at about 51% of the market in 2026, with the remaining share divided across classical and basal media, specialty and stem-cell media, and serum-containing media. Serum-free and chemically defined media are the largest and fastest-growing product because regulatory preference for animal-component-free manufacturing and the need for reproducibility and safety in biologics and therapies favour them, and they command premium prices; Ajinomoto created Japan's first serum-free medium in the 1980s. Classical and basal media, including DMEM and RPMI, remain widely used in research and as formulation bases. Specialty and stem-cell media, including the StemFit medium for induced pluripotent and embryonic stem cells and clinical-grade media for cell and gene therapy, are a high-value segment tied to regenerative medicine. Serum-containing media, using fetal bovine serum, are declining as serum-free alternatives grow. The dominance of serum-free and chemically defined media reflects the quality and regulatory demands of biologics and therapies.

Market by Application

By application, the market comprises biopharmaceutical production, vaccine production, cell and gene therapy and regenerative medicine, research, and cultivated meat. Biopharmaceutical production holds the largest share, at about 55% of the market in 2026, with the remaining share divided across vaccine production, cell and gene therapy and regenerative medicine, research, and cultivated meat. Biopharmaceutical production is the leading application because manufacturing monoclonal antibodies, biosimilars and other biologics in cell lines such as CHO consumes the largest volumes of media, and Japan is expanding biologics and contract manufacturing capacity. Vaccine production uses media in Vero and other cell systems. Cell and gene therapy and regenerative medicine is a fast-growing application, using clinical-grade and stem-cell media, supported by Japan's induced pluripotent stem cell leadership and about 20 approved regenerative products. Research use in academia and industry is a steady application, and cultivated meat is an emerging application requiring food-grade serum-free media. The dominance of biopharmaceutical production reflects the scale of biologics manufacturing.

Market by End User

By end user, the market comprises biopharmaceutical and biotechnology companies, contract development and manufacturing organisations, academic and research institutes, cell-therapy developers, and cultivated-meat companies. Biopharmaceutical and biotechnology companies hold the largest share, at about 45% of the market in 2026, with the remaining share divided across contract manufacturers, academic and research institutes, cell-therapy developers, and cultivated-meat companies. Biopharmaceutical and biotechnology companies are the leading end user because they manufacture biologics at scale and consume the most media. Contract development and manufacturing organisations, including AGC Biologics and others building capacity in Japan, are a growing end user as manufacturing is outsourced. Academic and research institutes, including Kyoto University's stem-cell research, use media across research. Cell-therapy developers use clinical-grade media, and cultivated-meat companies such as IntegriCulture are an emerging end user. The dominance of biopharmaceutical companies reflects the scale of commercial manufacturing.

Market by Cell Type

By cell type, the market comprises Chinese hamster ovary cells, HEK293 cells, Vero cells, stem cells, and other cell systems. Chinese hamster ovary cells hold the largest share, as they are the workhorse cell line for producing monoclonal antibodies and many biologics and consume large volumes of serum-free and chemically defined media. HEK293 cells are widely used in gene therapy and viral-vector production. Vero cells are used in vaccine production. Stem cells, including induced pluripotent and embryonic stem cells, use specialty and clinical-grade media and are central to Japan's regenerative medicine. Other cell systems, including insect and food-relevant animal cells for cultivated meat, complete the segment. The dominance of Chinese hamster ovary cells reflects their central role in biologics manufacturing.

Geographic Analysis

Kanto Region (Tokyo, Yokohama, Saitama)

The Kanto region is the largest cluster, concentrating biopharmaceutical companies, research institutions and contract manufacturers, with AGC Biologics operating a cell-therapy and biologics site in Yokohama and FUJIFILM manufacturing cell culture media in Saitama Prefecture. The region's density of pharmaceutical head offices, research and manufacturing makes it the core of media demand and supply, spanning biologics production, research and clinical-grade media for therapies.

Kansai Region (Kyoto, Osaka, Kobe)

The Kansai region is a major cluster for regenerative medicine and pharmaceuticals, anchored by Kyoto University, where Professor Yamanaka pioneered induced pluripotent stem cells, and by the Kobe regenerative-medicine cluster and Osaka's pharmaceutical base. The region drives demand for stem-cell and clinical-grade media and is central to Japan's cell and gene therapy development, linking academic research to clinical and commercial use.

Chubu Region and National Supply

The Chubu region, including Aichi Prefecture, hosts cell culture media manufacturing by FUJIFILM Irvine Scientific, contributing to domestic supply. Across Japan, demand is served by a combination of domestic producers such as Ajinomoto and FUJIFILM and imports, which account for about half of consumption, reflecting the market's preference for premium, high-quality media and the global nature of the leading suppliers. National supply is shaped by the balance of domestic GMP capacity and imported specialty media.

Pricing Analysis

Pricing in cell culture media reflects formulation complexity, quality grade, and application. Serum-free and chemically defined media and clinical-grade GMP media command the highest prices, reflecting their formulation, quality control and regulatory requirements, while classical and basal media used in research are lower priced. Japan is a premium market with demanding quality specifications, and imported specialty media carry high prices, with about half of consumption imported.

Several factors set price. Formulation complexity is central, as serum-free and chemically defined media with defined components cost more than classical media. Quality grade raises price, with clinical-grade GMP media for cell and gene therapy priced well above research-grade media. Application matters, as media for commercial biologics and clinical therapies command more than research media. Volume and supply source affect price, with large-volume manufacturing media and imported specialty media priced differently. Regulatory and safety requirements, including animal-component-free status, support premium pricing. The trajectory of pricing depends on the shift to serum-free and clinical-grade media, on domestic GMP capacity that may moderate import premiums, and on cost pressure from cultivated meat, which needs low-cost food-grade media, and the balance points to continued premium pricing for high-grade media alongside cost focus in emerging food applications.

Competitive Landscape

The market is served by domestic majors, global suppliers, and specialty producers. Ajinomoto Co., Inc. is a leading domestic player, having created Japan's first serum-free medium in the 1980s, developed the StemFit medium for stem cells, operated the CELLiST media business, and formed Ajinomoto Kohjin Bio as the first contract manufacturer in Japan for clinical-grade cell and gene therapy media. FUJIFILM Irvine Scientific, Inc., acquired by FUJIFILM for about USD 800 million, manufactures cell culture media in Saitama and Aichi in Japan as well as internationally, serving biologics production, cell therapy and fertility. Global suppliers Thermo Fisher Scientific, through its Gibco media, and Merck KGaA, through its life-science business, supply a large share of imported media, alongside Corning. FUJIFILM Wako Pure Chemical Corporation, Nissan Chemical Corporation, Kohjin Bio Co., Ltd., Nihon Pharmaceutical Co., Ltd. and Nacalai Tesque, Inc. supply media and reagents, and IntegriCulture develops food-grade media for cultivated meat.

Competition turns on formulation and quality, GMP and clinical-grade capability, technical support, and supply reliability, and the market combines strong domestic producers with major global suppliers that provide much of the imported premium media. The shift to serum-free and clinical-grade media, the growth of regenerative medicine, and capacity investment favour producers with high-quality, animal-component-free and GMP portfolios, and Ajinomoto and FUJIFILM give Japan two globally significant domestic media producers, while global majors compete strongly in imported media. The field is likely to intensify as biologics, cell and gene therapy, and cultivated meat expand demand.

Key Players

The active companies in the market as of September 2026 include:

• Ajinomoto Co., Inc.
• FUJIFILM Irvine Scientific, Inc.
• Thermo Fisher Scientific
• Merck KGaA (MilliporeSigma)
• FUJIFILM Wako Pure Chemical Corporation
• Nissan Chemical Corporation
• Kohjin Bio Co., Ltd.
• Nihon Pharmaceutical Co., Ltd.
• Nacalai Tesque, Inc.
• Corning Incorporated
• IntegriCulture Inc.
• Other Companies

Voice of Customer

Process development lead, biopharmaceutical company (Japan): "For our CHO-based antibody production, serum-free and chemically defined media are now the standard, because regulators and our quality systems require animal-component-free, reproducible processes. We pay a premium for high-quality media and value technical support and supply reliability, and we work with both domestic producers and the global suppliers who provide much of the specialty media we import."

Manufacturing manager, cell therapy developer (Japan): "Clinical-grade GMP media are essential for our regenerative-medicine products, and having a domestic contract manufacturer for clinical-grade media has been important for supply security and regulatory alignment. The cost is high, but for cell therapy the quality and traceability of the media are non-negotiable."

R&D director, cultivated meat startup (Japan): "Our challenge is media cost, since food-grade cultivated meat cannot use expensive serum-based media, so we develop serum-free systems to bring cost down. The media is the largest cost in cultivated meat, and progress on low-cost, food-grade formulations is what will make the product viable."

Analyst Perspective

Japan's cell culture media market is a mature, high-value market anchored in biologics manufacturing and distinguished by the country's leadership in regenerative medicine. The core demand comes from producing monoclonal antibodies and other biologics in cell lines such as CHO, which consume large volumes of serum-free and chemically defined media, now about 51% of the market, as regulation and quality favour animal-component-free processes. The distinctive strength is regenerative medicine: Japan pioneered induced pluripotent stem cells, its regenerative-medicine market was about USD 1.34 billion in 2024 and is projected to more than double by 2030, and it has approved about 20 regenerative products, creating demand for specialty and clinical-grade media. Japan is unusual in hosting two globally significant domestic media producers, Ajinomoto and FUJIFILM Irvine Scientific, alongside major global suppliers.

The honest considerations are import dependence, cost, and the still-early scale of some applications. Japan imports about half of its media consumption, reflecting the global nature of the leading suppliers and the premium placed on specialty media, and domestic GMP capacity, while growing, does not yet displace this. Serum-free, chemically defined and clinical-grade media are expensive, which is a barrier for cost-sensitive applications, most notably cultivated meat, where media cost is the central challenge and the food-grade market is nascent. Regenerative medicine, though a global leader in science, has produced limited commercial volumes so far, so the specialty-media opportunity is real but developing. The market should be assessed on the growth of biologics manufacturing, the pace of regenerative-medicine commercialisation, the shift to serum-free and clinical-grade media, and domestic capacity, and Japan's strong biologics base, regenerative-medicine leadership, and two domestic media majors support steady growth, with cell and gene therapy and cultivated meat as the higher-growth, higher-uncertainty opportunities.

Strategic Recommendations

For media producers, the priority is to expand serum-free, chemically defined and clinical-grade GMP capacity, because demand is shifting decisively toward animal-component-free and high-quality media across biologics and therapies, and this is where value and growth concentrate. Companies should invest in domestic GMP manufacturing to serve regenerative medicine and reduce import reliance, strengthen serum-free and chemically defined portfolios for biologics, and provide the technical support and quality that Japan's demanding customers require. Building clinical-grade capability for cell and gene therapy, as Ajinomoto Kohjin Bio has done, and pursuing low-cost food-grade media for cultivated meat position producers for growth applications.

For biopharmaceutical companies and contract manufacturers, the recommendation is to secure reliable, high-quality serum-free media supply and to work with domestic and global producers on process and cost, given the premium on specialty media and the roughly half of consumption that is imported. For cell-therapy developers, domestic clinical-grade media support supply security and regulatory alignment. For cultivated-meat companies, driving down serum-free media cost is the central task, as media is the largest cost. For policymakers, support for domestic GMP capacity, regenerative-medicine commercialisation, and cultivated-meat innovation strengthens the ecosystem. For investors, this is a mature, high-value market with strong biologics demand and a distinctive regenerative-medicine base, to evaluate on serum-free and clinical-grade growth, domestic capacity, and the pace of cell and gene therapy and cultivated-meat demand, recognising Japan's rare position of hosting two globally significant domestic media producers.